| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Unit (T.D., J.-P.V., J.T.P., T.J.G.) and Program in Membrane Biology (J.-P.V.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Thomas J. Gardella, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: Gardella{at}helix.mgh.harvard.edu.
PTH and PTHrP use the same G protein-coupled receptor, the PTH/PTHrP receptor (PTHR), to mediate their distinct biological actions. The extent to which the mechanisms by which the two ligands bind to the PTHR differ is unclear. We examined this question using several pharmacological and biophysical approaches. Kinetic dissociation and equilibrium binding assays revealed that the binding of [125I]PTHrP(1–36) to the PTHR was more sensitive to GTP
S (added to functionally uncouple PTHR-G protein complexes) than was the binding of [125I]PTH(1–34) (
75% maximal inhibition vs.
20%). Fluorescence resonance energy transfer-based kinetic analyses revealed that PTHrP(1–36) bound to the PTHR more slowly and dissociated from it more rapidly than did PTH(1–34). The cAMP signaling response capacity of PTHrP(1–36) in cells decayed more rapidly than did that of PTH(1–34) (t1/2 =
1 vs.
2 h). Divergent residue 5 in the ligand, Ile in PTH and His in PTHrP, was identified as a key determinant of the altered receptor-interaction responses exhibited by the two peptides. We conclude that whereas PTH and PTHrP bind similarly to the G protein-coupled PTHR conformation (RG), PTH has a greater capacity to bind to the G protein-uncoupled conformation (R0) and, hence, can produce cumulatively greater signaling responses (via R0
RG isomerization) than can PTHrP. Such conformational selectivity may relate to the distinct modes by which PTH and PTHrP act biologically, endocrine vs. paracrine, and may help explain reported differences in the effects that the ligands have on calcium and bone metabolism when administered to humans.
This article has been cited by other articles:
![]() |
D. Miao, H. Su, B. He, J. Gao, Q. Xia, M. Zhu, Z. Gu, D. Goltzman, and A. C. Karaplis Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein PNAS, December 23, 2008; 105(51): 20309 - 20314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Okazaki, S. Ferrandon, J.-P. Vilardaga, M. L. Bouxsein, J. T. Potts Jr, and T. J. Gardella Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation PNAS, October 28, 2008; 105(43): 16525 - 16530. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. U. Miedlich and A. B. Abou-Samra Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E665 - E671. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Gardella Crystal Structure of the Extracellular Domain of the PTH/PTHrP Receptor IBMS BoneKEy, May 1, 2008; 5(5): 171 - 175. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |